Delivery Order SPE2DR25D1202-SPE2DR26F72SL
- Not listed
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on November 28, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $6,715.21. This firm fixed-price delivery order is set to be completed by December 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a pediatric pharmaceutical delivery under the DLA's medical supply...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a contract ceiling value of $10,361.60. This is a firm fixed-price delivery order with an ultimate completion date of September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive bidding with no set-aside designation. This...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,846.27 by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL) with a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of September 4, 2025, and performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under a larger contract vehicle, representing...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $41,621.24 by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml). The contract utilizes firm fixed pricing and is classified as a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,269.01 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on October 24, 2025, with completion targeted for October 27, 2025. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- AmerisourceBergen Drug Corp received a $2,369.47 delivery order award from the Defense Logistics Agency (DLA) on July 17, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL). This firm fixed-price, competitively awarded contract has an ultimate completion date of July 18, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on October 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $28,295.68. The contract is structured as a firm fixed price delivery order with an ultimate completion date of October 31, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $7,769.38. This firm fixed-price delivery order, with an ultimate completion date of November 7, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $17,574.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 9, 2025, with completion targeted for September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,576.23 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic (0.25-0.5 mg/dose) pens in 3ml quantities. This firm fixed-price delivery order, with an ultimate completion date of August 27, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F72SLDelivery Order
AmerisourceBergen Drug Corp was awarded a $6,356.08 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on December 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL) with an ultimate completion date of December 4, 2025. The award, which was competitively procured without a set-aside designation, will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. The delivery order represents a routine pharmaceutical supply transaction supporting federal medical needs, likely serving military healthcare systems and the Defense Health Agency. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains extensive federal contract portfolios with the DLA Medical Supply Chain, supplying a broad range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's demonstrated capability to fulfill diverse pharmaceutical requirements through competitive federal procurement makes it well-positioned as a prime vendor for military and veteran healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 12/2/25 |